%0 Journal Article %T New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine %A Hubert H. Fernandez %A Katie M. McCown %A Janet Romrell %A Martha E. Trieschmann %A Joseph H. Friedman %A Charles E. Jacobson IV and Michael S. Okun %J Drug Target Insights %D 2012 %I %X Atypical antipsychotics (AA) are commonly used to manage drug-induced psychosis (DIP) in parkinsonian patients. In the treatment of schizophrenia, AA¡¯s have been associated with increasing reports of new-onset diabetes mellitus (DM). This study examined the risk of developing new-onset DM among parkinsonian patients on long-term, low dose quetiapine. Fifty-three parkinsonian subjects (mean age: 71.3 years) taking an average quetiapine dose of 70.5 mg/day (range: 12.5¨C350 mg/day) for a mean duration of 21.3 months (range 3¨C61 months) were reviewed. Eight out of 53 subjects carried a diagnosis of DM prior to quetiapine treatment. Four out of 45 patients (8.9%) met criteria for new diagnosis of DM, giving a total prevalence rate of 22.6% (12 out of 53). This prevalence rate of 22.6% was slightly higher than that reported in the aged-matched general population (year 2003 DM prevalence = 17.3% for 65¨C74 years) but methodological differences could explain the difference. Larger epidemiologic studies will be needed to confirm these results as they could potentially impact a significant number of patients. %U http://www.la-press.com/new-onset-diabetes-mellitus-among-parkinsonian-patients-treated-with-l-article-a630